Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
OncoResponse
OncoResponse is an immuno-oncology company that provides cancer research into immunotherapies and the latest technologies for oncologists.
Sector
Subsector
Keywords
Location
total rounds
total raised
Jounce Therapeutics
Jounce Therapeutics is a clinical-stage immunotherapy company.
Sector
Subsector
Keywords
Location
total rounds
total raised
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Pyxis Oncology
Pyxis Oncology develops next-gen therapeutics to treat difficult cancers.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Coherus Biosciences
announced date
price
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 20.05.2020. Their latest investor K2 HealthVentures. Their latest round Post-IPO Equity
EcoR1 Capital
EcoR1 Capital is a biotech-focused investment advisory firm based in San Francisco.
Sector
Subsector
Location
count Of Investments
count Of Exists
K2 HealthVentures
K2 HealthVentures provides long-term financing to innovative companies in life sciences and healthcare.
Sector
Subsector
Location
count Of Investments
count Of Exists
Atlas Venture
Atlas Venture invests in biotech startups with seed and early stage venture investments.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Co-Investors
Investors11
Number of lead investors
Number of investors
K2 HealthVentures
K2 HealthVentures provides long-term financing to innovative companies in life sciences and healthcare.
Sector
Subsector
Location
count Of Investments
count Of Exists
Elliott Sigal
Elliott Sigal, M.D., Ph.D. joined NEA as a Venture Partner and Senior Advisor in 2014. He is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. He was a principal architect of the successful Biopharma Transformation Strategy of the company. He has been instrumental in increasing R&D productivity, developing the company’s strategy in biologics and acquiring external innovation in Bristol’s String of Pearls initiative. Under his leadership, fourteen new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer), Onglyza and Kombiglyze (Diabetes), Nulojix (Transplantation), Eliquis (Anticoagulant), Yervoy (Melanoma), and Forxiga (Diabetes). Among his accomplishments in various therapeutic areas was building BMS research into a lead position in the promising area of immuno-oncology. In 2012, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. Dr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. Dr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). Prior to medical school he studied engineering at Purdue University, where he received a B.S., M.S., and Ph.D. Dr. Sigal serves as a member of the Board of Directors for the Mead Johnson Nutrition Company and the Melanoma Research Alliance.
current job
count Of Investments
Atlas Venture
Atlas Venture invests in biotech startups with seed and early stage venture investments.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Michael Gladstone
Michael Gladstone is an associate in the life sciences group. Prior to joining Atlas in 2012, Michael was a senior associate consultant in the life sciences practice at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. While at L.E.K. Michael also served as head of client development for Inspire, a volunteer consulting firm staffed by junior consultants at L.E.K., Bain & Company, Parthenon, and Monitor Group. He led, designed, and organized teams of consultants for strategy projects for six non-profit organizations in the greater Boston area. Prior to that, Michael was a Massachusetts Life Sciences Center Fellow at Eutropics, a Dana Farber Cancer Institute spin out, where he helped develop BH3 domain focused therapeutics and companion diagnostics for multiple myeloma and other malignancies. Previously, Michael worked in the viral pathogenesis department of Beth Israel Deaconess Medical Center where he conducted research on cellular HIV vaccines with Harvard Medical School Professor Norman Letvin. His research focused on elucidating the role of interleukin-21 on the cellular immune response to viral antigens.
current job
count Of Investments
People
Founders1
Michael Gladstone
Michael Gladstone is an associate in the life sciences group. Prior to joining Atlas in 2012, Michael was a senior associate consultant in the life sciences practice at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. While at L.E.K. Michael also served as head of client development for Inspire, a volunteer consulting firm staffed by junior consultants at L.E.K., Bain & Company, Parthenon, and Monitor Group. He led, designed, and organized teams of consultants for strategy projects for six non-profit organizations in the greater Boston area. Prior to that, Michael was a Massachusetts Life Sciences Center Fellow at Eutropics, a Dana Farber Cancer Institute spin out, where he helped develop BH3 domain focused therapeutics and companion diagnostics for multiple myeloma and other malignancies. Previously, Michael worked in the viral pathogenesis department of Beth Israel Deaconess Medical Center where he conducted research on cellular HIV vaccines with Harvard Medical School Professor Norman Letvin. His research focused on elucidating the role of interleukin-21 on the cellular immune response to viral antigens.
current job
count Of Investments
Michael Gladstone
Employee Profiles31
Chris Beans
Associate director of information technology
Chandra Adams
Senior director, intellectual property